While direct evidence for IL-1β–TRPV1 crosstalk in atherosclerosis is lacking, future investigations could reveal whether sensory neuroimmune desensitization contributes to the plaque-stabilizing effects of anti-cytokine therapy. This evidence concerns the gene TRPV1 and atherosclerosis.